Fri 14-08-2020 13:13 PM
France welcomes freeze on Palestinian territories annexation
PARIS, 14th August 2020 (WAM) - France welcomed the agreement between the UAE and Israel to further stop Israeli annexation of Palestinian territories.
In a statement issued Thursday, the French Ministry of Foreign Affairs said Israel's decision to suspend its planned annexation of areas of the occupied West Bank under the historic agreement is a "positive step".
"The accord paved the way for a resumption of talks between Israelis and Palestinians with the aim to establish two states, which is the only option to achieve peace in the region," the Ministry added.
WAM/Hassan Bashir/Tariq alfaham
France welcomes freeze on Palestinian territories annexation
PARIS, 14th August 2020 (WAM) - France welcomed the agreement between the UAE and Israel to further stop Israeli annexation of Palestinian territories.
In a statement issued Thursday, the French Ministry of Foreign Affairs said Israel's decision to suspend its planned annexation of areas of the occupied West Bank under the historic agreement is a "positive step".
"The accord paved the way for a resumption of talks between Israelis and Palestinians with the aim to establish two states, which is the only option to achieve peace in the region," the Ministry added.
WAM/Hassan Bashir/Tariq alfaham
launch
The Xinhua Dictionary launches 12th edition.
launch into
lauch out into
He launched-into a two hour sales pitch.
The 12th editon of Xinhua Dictionary. Published on Monday after nine years since its last edition. has added new words and definitions shaped by the internet and social progressprogress. reflecting the development of the country and characteristics of the times.
The Xinhua Dictionary launches 12th edition.
launch into
lauch out into
He launched-into a two hour sales pitch.
The 12th editon of Xinhua Dictionary. Published on Monday after nine years since its last edition. has added new words and definitions shaped by the internet and social progressprogress. reflecting the development of the country and characteristics of the times.
【2021MEM#考研英语(二)真题#系列（2012年真题）Part 3-全文精彩翻译】#MEM##MBA##MPAcc#
In 2010，a federal judge shook America's biotech industry to its core. Companies had won patents for isolated DNA for decades-by 2005 some 20% of human genes were patented. But in March 2010 a judge ruled that genes were unpatentable. Executives were violently agitated. The Biotechnology Industry Organisation (BIO), a trade group, assured members that this was just a “preliminary step” in a longer battle.
2010年，一名联邦法官引起了美国生物技术行业的巨大震动。几十年来，许多公司获得了分离DNA的专利。截至2005年，大约20%的人类基因被授予了专利。但在2010年3月，一名法官裁决基因不具有专利性。高管们因此惴惴不安。生物技术工业组织BIO是一个贸易组织，它向其成员保证它绝不会屈服于此判决。
On July 29th they were relieved, at least temporarily. A federal appeals court overturned the prior decision, ruling that Myriad Genetics could indeed hold patents to two genes that help forecast a woman's risk of breast cancer. The chief executive of Myriad, a company in Utah, said the ruling was a blessing to firms and patients alike.
7月29日，他们至少暂时松了一口气。因为一家联邦上诉法院推翻了之前的判决，裁定Myriad基因公司可以享有两个帮助预测女性乳腺癌的基因专利。位于犹他州的Myriad公司的首席执行官说：该判决对于公司和患者不啻是一个福音。
But as companies continue their attempts at personalised medicine, the courts will remain rather busy. The Myriad case itself is probably not over. Critics make three main arguments against gene patents: a gene is a product of nature, so it may not be patented; gene patents suppress innovation rather than reward it; and patents' monopolies restrict access to genetic tests such as Myriad's. A growing number seem to agree. Last year a federal task-force urged reform for patents related to genetic tests. In October the Department of Justice filed a brief in the Myriad case, arguing that an isolated DNA molecule “is no less a product of nature... than are cotton fibers that have been separated from cotton seeds.”
但是，当许多公司继续尝试个性化药品时，法院将继续处理此类案件。Myriad案本身可能还未结束。批评人士提出三个反对基因专利的理由：基因是自然的产物，所以不能被授予专利；基因专利抑制了创新，而不是鼓励创新；专利垄断限制他人进行基因测试，比如Myriad公司的垄断。越来越多的人似乎同意这种说法。去年，联邦特别小组敦促进行与基因检测相关的专利改革。10月份，司法部在针对Myriad案中提交的一份陈辩书发表评论：单个DNA分子和“从棉籽上分离出来的棉纤维一样，都是自然产物”。
Despite the appeals court's decision, big questions remain unanswered. For example, it is unclear whether the sequencing of a whole genome violates the patents of individual genes within it. The case may yet reach the Supreme Court.
尽管上诉法院作出了这样的裁决，但是重要的问题仍然没有得到回答。比如，整个基因组序列是否违背了其中单个基因的专利仍无定论。本案可能还要上诉到最高法院。
As the industry advances, however, other suits may have an even greater impact. Companies are unlikely to file many more patents for human DNA molecules - most are already patented or in the public domain. Firms are now studying how genes interact, looking for correlations that might be used to determine the causes of disease or predict a drug’s efficacy. Companies are eager to win patents for ‘connecting the dots’, explains Hans Sauer, a lawyer for the BIO.
但是，随着该行业的发展，其他的诉讼可能会产生更大的影响力。公司不大可能申请到更多的人类DNA专利—大部分已经被申请或者属于公共领域。目前，各公司正在研究基因是如何相互作用的，以寻找它们之间的关联性，从而用来判断疾病的起因或者预测药物的功效。生物技术工业组织（BIO）的律师Hans Sauer解释道：“公司渴望获得专利以便理清头绪。”
Their success may be determined by a suit related to this issue, brought by the Mayo Clinic, which the Supreme Court will hear in its next term. The BIO recently held a convention which included sessions to coach lawyers on the shifting landscape for patents. Each meeting was packed.
他们的成功可能取决于Mayo诊所带来的与此案相关的诉讼，最高法院将在下一轮听证此案。最近生物技术工业组织（BIO）举行了一场大会，其中有些会议专门指导律师处理目前摇摆不定局面下的专利问题，每个会议都人满为患。
In 2010，a federal judge shook America's biotech industry to its core. Companies had won patents for isolated DNA for decades-by 2005 some 20% of human genes were patented. But in March 2010 a judge ruled that genes were unpatentable. Executives were violently agitated. The Biotechnology Industry Organisation (BIO), a trade group, assured members that this was just a “preliminary step” in a longer battle.
2010年，一名联邦法官引起了美国生物技术行业的巨大震动。几十年来，许多公司获得了分离DNA的专利。截至2005年，大约20%的人类基因被授予了专利。但在2010年3月，一名法官裁决基因不具有专利性。高管们因此惴惴不安。生物技术工业组织BIO是一个贸易组织，它向其成员保证它绝不会屈服于此判决。
On July 29th they were relieved, at least temporarily. A federal appeals court overturned the prior decision, ruling that Myriad Genetics could indeed hold patents to two genes that help forecast a woman's risk of breast cancer. The chief executive of Myriad, a company in Utah, said the ruling was a blessing to firms and patients alike.
7月29日，他们至少暂时松了一口气。因为一家联邦上诉法院推翻了之前的判决，裁定Myriad基因公司可以享有两个帮助预测女性乳腺癌的基因专利。位于犹他州的Myriad公司的首席执行官说：该判决对于公司和患者不啻是一个福音。
But as companies continue their attempts at personalised medicine, the courts will remain rather busy. The Myriad case itself is probably not over. Critics make three main arguments against gene patents: a gene is a product of nature, so it may not be patented; gene patents suppress innovation rather than reward it; and patents' monopolies restrict access to genetic tests such as Myriad's. A growing number seem to agree. Last year a federal task-force urged reform for patents related to genetic tests. In October the Department of Justice filed a brief in the Myriad case, arguing that an isolated DNA molecule “is no less a product of nature... than are cotton fibers that have been separated from cotton seeds.”
但是，当许多公司继续尝试个性化药品时，法院将继续处理此类案件。Myriad案本身可能还未结束。批评人士提出三个反对基因专利的理由：基因是自然的产物，所以不能被授予专利；基因专利抑制了创新，而不是鼓励创新；专利垄断限制他人进行基因测试，比如Myriad公司的垄断。越来越多的人似乎同意这种说法。去年，联邦特别小组敦促进行与基因检测相关的专利改革。10月份，司法部在针对Myriad案中提交的一份陈辩书发表评论：单个DNA分子和“从棉籽上分离出来的棉纤维一样，都是自然产物”。
Despite the appeals court's decision, big questions remain unanswered. For example, it is unclear whether the sequencing of a whole genome violates the patents of individual genes within it. The case may yet reach the Supreme Court.
尽管上诉法院作出了这样的裁决，但是重要的问题仍然没有得到回答。比如，整个基因组序列是否违背了其中单个基因的专利仍无定论。本案可能还要上诉到最高法院。
As the industry advances, however, other suits may have an even greater impact. Companies are unlikely to file many more patents for human DNA molecules - most are already patented or in the public domain. Firms are now studying how genes interact, looking for correlations that might be used to determine the causes of disease or predict a drug’s efficacy. Companies are eager to win patents for ‘connecting the dots’, explains Hans Sauer, a lawyer for the BIO.
但是，随着该行业的发展，其他的诉讼可能会产生更大的影响力。公司不大可能申请到更多的人类DNA专利—大部分已经被申请或者属于公共领域。目前，各公司正在研究基因是如何相互作用的，以寻找它们之间的关联性，从而用来判断疾病的起因或者预测药物的功效。生物技术工业组织（BIO）的律师Hans Sauer解释道：“公司渴望获得专利以便理清头绪。”
Their success may be determined by a suit related to this issue, brought by the Mayo Clinic, which the Supreme Court will hear in its next term. The BIO recently held a convention which included sessions to coach lawyers on the shifting landscape for patents. Each meeting was packed.
他们的成功可能取决于Mayo诊所带来的与此案相关的诉讼，最高法院将在下一轮听证此案。最近生物技术工业组织（BIO）举行了一场大会，其中有些会议专门指导律师处理目前摇摆不定局面下的专利问题，每个会议都人满为患。
✋热门推荐